PARP inhibitors for triple negative breast cancer: A literature review
DOI:
https://doi.org/10.33448/rsd-v12i6.42367Keywords:
Triple Negative Breast Neoplasms; BRCA1 gene; Poly(ADP-ribose) Polymerase Inhibitors; BRCA2 gene.Abstract
The study intends to analyze, through this review, the efficacy of PARP inhibitor drugs, based on the following criteria: overall survival (OS), progression-free survival (PFS), toxicity and tolerability (adverse events (AEs) presented by patients). This study consists of a systematic review of the literature about the effectiveness of PARP inhibitor drugs, through data from OS, PFS and AEs presented. The systematic review was based on the methodological guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the guiding question of the study was established through an acronym defined as PICO, that is, Population, Intervention/Exposure, Comparison and “Outcome”. We included studies that contained all investigator-defined efficacy data and that compared therapy with i-PARP and without i-PARP. Seven articles were included that contained OS, PFS and EA data and that compared i-PAPR dose or drug regimens. Three of the seven studies looked at the efficacy of the Gemcitabine + Carboplatin + Iniparib regimen and demonstrated that the addition of Iniparib had a significant effect on efficacy. Two other studies showed good results with the combination of other drugs with i-PARP Olaparib. The studies included in this review corroborate the use of i-PARPs, mainly Iniparib and Olaparib, together with conventional chemotherapy demonstrating efficacy for TNBC.
References
About Breast Cancer. (2022). American Cancer SOciety. https://www.cancer.org/cancer/types/breast-cancer/about.html
Batalini, F., Xiong, N., Tayob, N., Polak, M., Eismann, J., Cantley, L. C., Shapiro, G. I., Adalsteinsson, V., Winer, E. P., Konstantinopoulos, P. A., D’Andrea, A., Swisher, E. M., Matulonis, U. A., Wulf, G. M., & Mayer, E. L. (2022). Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. Clinical Cancer Research, 28(8), 1493–1499. https://doi.org/10.1158/1078-0432.CCR-21-3045
Bonde, G. V., Yadav, S. K., Chauhan, S., Mittal, P., Ajmal, G., Thokala, S., & Mishra, B. (2018). Lapatinib nano-delivery systems: A promising future for breast cancer treatment. Expert Opinion on Drug Delivery, 15(5), 495–507. https://doi.org/10.1080/17425247.2018.1449832
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 434(7035), 913–917. https://doi.org/10.1038/nature03443
buitrago, et al. (2011). Fatores prognósticos em câncer de mama / Prognostic factors in breast cancer. https://pesquisa.bvsalud.org/portal/resource/pt/lil-619069
Chen, Z., Wang, X., Li, X., Zhou, Y., & Chen, K. (2021). Deep exploration of PARP inhibitors in breast cancer: Monotherapy and combination therapy. Journal of International Medical Research, 49(2), 030006052199101. https://doi.org/10.1177/0300060521991019
Conceito e Magnitude: Definição do câncer de mama e dados de incidência e mortalidade no Brasil. (2020). Instituto Nacional de Câncer - INCA. https://www.gov.br/inca/pt-br/assuntos/gestor-e-profissional-de-saude/controle-do-cancer-de-mama/conceito-e-magnitude#:~:text=O%20c%C3%A2ncer%20de%20mama%20%C3%A9%20o%20mais%20incidente%20em%20mulheres,novos%20por%20c%C3%A2ncer%20em%20mulheres.
Corrêa. ([s.d.]). Câncer de mama triplo negativo e sua associação com ancestralidade africana. https://repositorio.ufba.br/bitstream/ri/1556/1/3498.pdf
Diéras, V., Bonnefoi, H., Alba, E., Awada, A., Coudert, B., Pivot, X., Gligorov, J., Jager, A., Zambelli, S., Lindeman, G. J., Charpentier, E., Emmons, G. T., Garcia-Ribas, I., Paridaens, R., & Verweij, J. (2019). Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: A phase II randomized open-label study with pharmacokinetics. Breast Cancer Research and Treatment, 177(2), 383–393. https://doi.org/10.1007/s10549-019-05305-w
Drew, Y. (2015). The development of PARP inhibitors in ovarian cancer: From bench to bedside. British Journal of Cancer, 113(S1), S3–S9. https://doi.org/10.1038/bjc.2015.394
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., Martin, N. M. B., Jackson, S. P., Smith, G. C. M., & Ashworth, A. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434(7035), 917–921. https://doi.org/10.1038/nature03445
Ferreira, E. N., Brianese, R. C., de Almeida, R. V. B., Drummond, R. D., de Souza, J. E., da Silva, I. T., de Souza, S. J., & Carraro, D. M. (2019). Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer. Translational Oncology, 12(11), 1453–1460. https://doi.org/10.1016/j.tranon.2019.07.016
Gelmon, K., Dent, R., Mackey, J. R., Laing, K., McLeod, D., & Verma, S. (2012). Targeting triple-negative breast cancer: Optimising therapeutic outcomes. Annals of Oncology, 23(9), 2223–2234. https://doi.org/10.1093/annonc/mds067
Helleday, T. (2011). The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings. Molecular Oncology, 5(4), 387–393. https://doi.org/10.1016/j.molonc.2011.07.001
Hurvitz, S. A., Gonçalves, A., Rugo, H. S., Lee, K.-H., Fehrenbacher, L., Mina, L. A., Diab, S., Blum, J. L., Chakrabarti, J., Elmeliegy, M., DeAnnuntis, L., Gauthier, E., Czibere, A., Tudor, I. C., Quek, R. G. W., Litton, J. K., & Ettl, J. (2020). Talazoparib in Patients with a Germline BRCA -Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. The Oncologist, 25(3), e439–e450. https://doi.org/10.1634/theoncologist.2019-0493
Iglehart, J. D., & Silver, D. P. (2009). Synthetic Lethality—A New Direction in Cancer-Drug Development. New England Journal of Medicine, 361(2), 189–191. https://doi.org/10.1056/NEJMe0903044
Keung, M., Wu, Y., & Vadgama, J. (2019). PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. Journal of Clinical Medicine, 8(4), 435. https://doi.org/10.3390/jcm8040435
LaFargue, C. J., Dal Molin, G. Z., Sood, A. K., & Coleman, R. L. (2019). Exploring and comparing adverse events between PARP inhibitors. The Lancet Oncology, 20(1), e15–e28. https://doi.org/10.1016/S1470-2045(18)30786-1
Li, Y., Yang, D., Chen, P., Yin, X., Sun, J., Li, H., & Ren, G. (2019). Efficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: A network meta-analysis. Aging, 11(16), 6286–6311. https://doi.org/10.18632/aging.102188
Litton, J. K., Hurvitz, S. A., Mina, L. A., Rugo, H. S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., Roché, H., Im, Y.-H., Eiermann, W., Quek, R. G. W., Usari, T., Lanzalone, S., Czibere, A., Blum, J. L., Martin, M., & Ettl, J. (2020). Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: Final overall survival results from the EMBRACA trial. Annals of Oncology, 31(11), 1526–1535. https://doi.org/10.1016/j.annonc.2020.08.2098
Liu, J., Liu, Q., Li, Y., Li, Q., Su, F., Yao, H., Su, S., Wang, Q., Jin, L., Wang, Y., Lau, W. Y., Jiang, Z., & Song, E. (2020). Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: An open-label phase II trial. Journal for ImmunoTherapy of Cancer, 8(1), e000696. https://doi.org/10.1136/jitc-2020-000696
Liu, X., Wu, K., Zheng, D., Luo, C., Fan, Y., Zhong, X., & Zheng, H. (2021). Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 11, 742139. https://doi.org/10.3389/fonc.2021.742139
Lord, C. J., & Ashworth, A. (2017). PARP inhibitors: Synthetic lethality in the clinic. Science, 355(6330), 1152–1158. https://doi.org/10.1126/science.aam7344
Marotti, M. (2009). Por que revisar os critérios de resposta em tumores sólidos? Revista Da Associação Médica Brasileira, 55(4), 369–371. https://doi.org/10.1590/S0104-42302009000400005
Miglietta, F., Cinquini, M., Dieci, M. V., Cortesi, L., Criscitiello, C., Montemurro, F., Del Mastro, L., Zambelli, A., Biganzoli, L., Levaggi, A., Delle Piane, C., Marchiò, C., Calabrese, M., Fortunato, L., Franco, P., Meduri, B., Fittipaldo, V. A., & Gori, S. (2022). PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology. The Breast, 66, 293–304. https://doi.org/10.1016/j.breast.2022.10.014
Morales, J., Li, L., Fattah, F. J., Dong, Y., Bey, E. A., Patel, M., Gao, J., & Boothman, D. A. (2014). Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases. Critical Reviews in Eukaryotic Gene Expression, 24(1), 15–28. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2013006875
O’Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011). Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 364(3), 205–214. https://doi.org/10.1056/NEJMoa1011418
O’Shaughnessy, J., Schwartzberg, L., Danso, M. A., Miller, K. D., Rugo, H. S., Neubauer, M., Robert, N., Hellerstedt, B., Saleh, M., Richards, P., Specht, J. M., Yardley, D. A., Carlson, R. W., Finn, R. S., Charpentier, E., Garcia-Ribas, I., & Winer, E. P. (2014). Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 32(34), 3840–3847. https://doi.org/10.1200/JCO.2014.55.2984
Rodler, E., Sharma, P., Barlow, W. E., Gralow, J. R., Puhalla, S. L., Anders, C. K., Goldstein, L., Tripathy, D., Brown-Glaberman, U. A., Huynh, T.-T., Szyarto, C. S., Godwin, A. K., Pathak, H. B., Swisher, E. M., Radke, M. R., Timms, K. M., Lew, D. L., Miao, J., Pusztai, L., … Hortobagyi, G. N. (2023). Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): A randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Oncology, 24(2), 162–174. https://doi.org/10.1016/S1470-2045(22)00739-2
Rodler, E. T., Kurland, B. F., Griffin, M., Gralow, J. R., Porter, P., Yeh, R. F., Gadi, V. K., Guenthoer, J., Beumer, J. H., Korde, L., Strychor, S., Kiesel, B. F., Linden, H. M., Thompson, J. A., Swisher, E., Chai, X., Shepherd, S., Giranda, V., & Specht, J. M. (2016). Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer. Clinical Cancer Research, 22(12), 2855–2864. https://doi.org/10.1158/1078-0432.CCR-15-2137
Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020). PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Frontiers in Cell and Developmental Biology, 8, 564601. https://doi.org/10.3389/fcell.2020.564601
Sun, X., Wang, X., Zhang, J., Zhao, Z., Feng, X., Liu, L., & Ma, Z. (2021). Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review. The Breast, 60, 26–34. https://doi.org/10.1016/j.breast.2021.08.009
Taylor, A. M., Chan, D. L. H., Tio, M., Patil, S. M., Traina, T. A., Robson, M. E., & Khasraw, M. (2021). PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. Cochrane Database of Systematic Reviews, 2021(4). https://doi.org/10.1002/14651858.CD011395.pub2
Tsang, J. Y. S., & Tse, G. M. (2020). Molecular Classification of Breast Cancer. Advances in Anatomic Pathology, 27(1), 27–35. https://doi.org/10.1097/PAP.0000000000000232
Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Gelber, R. D., De Azambuja, E., Fielding, A., Balmaña, J., Domchek, S. M., Gelmon, K. A., Hollingsworth, S. J., Korde, L. A., Linderholm, B., Bandos, H., Senkus, E., Suga, J. M., Shao, Z., & Geyer, C. E. (2021). Adjuvant Olaparib for Patients with BRCA1—Or BRCA2 -Mutated Breast Cancer. New England Journal of Medicine, 384(25), 2394–2405. https://doi.org/10.1056/NEJMoa2105215
Wang, X., Wang, S.-S., Huang, H., Cai, L., Zhao, L., Peng, R.-J., Lin, Y., Tang, J., Zeng, J., Zhang, L.-H., Ke, Y.-L., Wang, X.-M., Liu, X.-M., Chen, Q.-J., Zhang, A.-Q., Xu, F., Bi, X.-W., Huang, J.-J., Li, J.-B., … South China Breast Cancer Group (SCBCG). (2021). Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial. JAMA, 325(1), 50. https://doi.org/10.1001/jama.2020.23370
Wu, T., Song, H., Xie, D., Hua, K., Hu, J., Deng, Y., Ji, C., & Fang, L. (2020). Mir-30b-5p Promotes Proliferation, Migration, and Invasion of Breast Cancer Cells via Targeting ASPP2. BioMed Research International, 2020, 1–12. https://doi.org/10.1155/2020/7907269
Yonemori, K., Shimomura, A., Yasojima, H., Masuda, N., Aogi, K., Takahashi, M., Naito, Y., Shimizu, S., Nakamura, R., Hashimoto, J., Yamamoto, H., Hirakawa, A., Michimae, H., Hamada, A., Yoshida, T., Sukigara, T., Tamura, K., & Fujiwara, Y. (2019). A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. European Journal of Cancer, 109, 84–91. https://doi.org/10.1016/j.ejca.2018.11.014
Zhang, Q., Shao, B., Tong, Z., Ouyang, Q., Wang, Y., Xu, G., Li, S., & Li, H. (2022). A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer. BMC Medicine, 20(1), 321. https://doi.org/10.1186/s12916-022-02527-6
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Amanda Marques Pinheiro; Ana Luiza Bastos Magalhães; Vera Aparecida Saddi; Andrea Alves Ribeiro
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
